Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Citation
Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis. 2017, 3 (3):230-232 JAAD Case RepPublisher
JAAD case reportsJournal
JAAD case reportsDOI
10.1016/j.jdcr.2017.02.001PubMed ID
28443318Abstract
Biologics have revolutionized the treatment of moderate-to-severe psoriasis, but serious infection is a risk with these immunosuppressive agents.1 An increased risk of tuberculosis (TB) reactivation in patients with latent TB infection is well recognized with antietumor necrosis factor (TNF)-a agents, as TNF has a central role in TB immunity, and antieTNF-a agents interfere with innate and cellmediated immune responses.2 Testing for and treating latent TB before starting therapy reduces the risk of reactivation of TB on biologic agentsItem Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jdcr.2017.02.001
Scopus Count
Collections
Related articles
- Ustekinumab: The "New Kid on the Block" in the Treatment of Psoriatic Arthritis.
- Authors: Torres T, Faria R
- Issue date: 2015 Dec
- The safety of ustekinumab for the treatment of psoriatic arthritis.
- Authors: López-Ferrer A, Laiz A, Puig L
- Issue date: 2017 Jun
- Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
- Authors: Thibodaux RJ, Triche MW, Espinoza LR
- Issue date: 2018 Jul
- Ustekinumab in psoriatic arthritis and related phenotypes.
- Authors: Dobbin-Sears I, Roberts J, O'Rielly DD, Rahman P
- Issue date: 2018 Oct
- Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.
- Authors: Lee MP, Desai RJ, Jin Y, Brill G, Ogdie A, Kim SC
- Issue date: 2019 Jun 1